董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Richard Paulson | 男 | President and Chief Executive Officer and Director | 58 | 未披露 | 未持股 | 2025-09-08 |
| Zhen Su | 男 | Director | 48 | 未披露 | 未持股 | 2025-09-08 |
| Christy J. Oliger | 女 | Director | 55 | 未披露 | 未持股 | 2025-09-08 |
| Barry E. Greene | 男 | Director | 61 | 19.82万美元 | 未持股 | 2025-09-08 |
| Deepa R. Pakianathan | 女 | Director | 60 | 16.26万美元 | 未持股 | 2025-09-08 |
| Chen Schor | 男 | Director | 52 | 未披露 | 未持股 | 2025-09-08 |
| Garen G. Bohlin | 男 | Director | 78 | 17.09万美元 | 未持股 | 2025-09-08 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Reshma Rangwala | 女 | Executive Vice President, Chief Medical Officer | 48 | 未披露 | 未持股 | 2025-09-08 |
| Lori Macomber | 女 | Executive Vice President, Chief Financial Officer and Treasurer | 54 | 未披露 | 未持股 | 2025-09-08 |
| Richard Paulson | 男 | President and Chief Executive Officer and Director | 58 | 未披露 | 未持股 | 2025-09-08 |
| Sohanya Cheng | 女 | Executive Vice President, Chief Commercial Officer | 42 | 未披露 | 未持股 | 2025-09-08 |
| Michael Mano | 男 | Senior Vice President, General Counsel and Secretary | 48 | 未披露 | 未持股 | 2025-09-08 |
| Stuart Poulton | 男 | Executive Vice President, Chief Development Officer | 52 | 未披露 | 未持股 | 2025-09-08 |
董事简历
中英对照 | 中文 | 英文- Richard Paulson
-
Richard Paulson，自2023年起在bluebird bio, Inc.董事会任职。自2021年以来，鲍尔森先生一直担任商业阶段制药公司Karyopharm Therapeutics的总裁、首席执行官兼董事。此前，Paulson先生曾于2018年至2021年担任Ipsen Pharmaceuticals执行副总裁兼Ipsen North America首席执行官，专注于肿瘤学、神经科学和罕见病的创新疗法和专科护理。在加入益普生之前，保尔森先生在安进工作了10年，在欧洲和北美担任过多个领导职务。保尔森先生获得了多伦多大学的工商管理硕士学位和萨斯喀彻温大学的市场营销和金融学士学位。
Richard Paulson,has served on Bluebird Bio, Inc. Board since 2023. Since 2021, Mr. Paulson has been President, Chief Executive Officer and Director at Karyopharm Therapeutics, a commercial-stage pharmaceutical company. Previously, Mr. Paulson was Executive Vice President of Ipsen Pharmaceuticals and Chief Executive Officer of Ipsen North America from 2018 to 2021 where he focused on innovative therapies and specialty care for oncology, neuroscience and rare diseases. Before joining Ipsen, Mr. Paulson work at Amgen for 10 years holding various leadership positions across Europe and North America. Mr. Paulson received his M.B.A. from the University of Toronto and his B.Com in marketing and finance from the University of Saskatchewan. - Richard Paulson，自2023年起在bluebird bio, Inc.董事会任职。自2021年以来，鲍尔森先生一直担任商业阶段制药公司Karyopharm Therapeutics的总裁、首席执行官兼董事。此前，Paulson先生曾于2018年至2021年担任Ipsen Pharmaceuticals执行副总裁兼Ipsen North America首席执行官，专注于肿瘤学、神经科学和罕见病的创新疗法和专科护理。在加入益普生之前，保尔森先生在安进工作了10年，在欧洲和北美担任过多个领导职务。保尔森先生获得了多伦多大学的工商管理硕士学位和萨斯喀彻温大学的市场营销和金融学士学位。
- Richard Paulson,has served on Bluebird Bio, Inc. Board since 2023. Since 2021, Mr. Paulson has been President, Chief Executive Officer and Director at Karyopharm Therapeutics, a commercial-stage pharmaceutical company. Previously, Mr. Paulson was Executive Vice President of Ipsen Pharmaceuticals and Chief Executive Officer of Ipsen North America from 2018 to 2021 where he focused on innovative therapies and specialty care for oncology, neuroscience and rare diseases. Before joining Ipsen, Mr. Paulson work at Amgen for 10 years holding various leadership positions across Europe and North America. Mr. Paulson received his M.B.A. from the University of Toronto and his B.Com in marketing and finance from the University of Saskatchewan.
- Zhen Su
-
Zhen Su，自2021年7月起担任临床阶段生物技术公司Marengo Therapeutics，Inc.（“Marengo”）的首席执行官。在加入Marengo之前，苏博士曾于2020年7月至2021年7月担任跨国科技公司默沙东 KGaA的高级副总裁兼肿瘤业务特许经营的美国&全球负责人，并于2019年至2021年5月担任高级副总裁兼肿瘤业务特许经营的全球负责人。苏博士于2017年至2019年担任生物制药公司EMD Serono，Inc.的首席医疗官。苏博士还在全球医疗保健公司赛诺菲肿瘤学和全球生物制药公司GSK担任领导职务，责任越来越大。在从事行业职业之前，苏博士曾在杜克大学医学院任职，在那里他领导了早期的肿瘤学临床研究，重点是基于mRNA和基于细胞的免疫疗法，然后是佛罗里达大学，在那里他担任细胞和基因治疗项目的主任。苏博士自2024年7月起担任生物医药平台公司Galvanize Therapeutics，Inc.的董事会成员，自2024年3月起担任上市生物制药公司CytomX医疗，Inc.的董事会成员，自2021年7月起担任Marengo的董事会成员。苏博士在德国德累斯顿工业大学获得医学博士学位，在加拿大多伦多大学获得工商管理硕士学位。
Zhen Su,served as Chief Executive Officer of Marengo Therapeutics, Inc. ("Marengo"), a clinical-stage biotechnology company, since July 2021. Prior to joining Marengo, Dr. Su served as Senior Vice President and U.S. & Global Head of Oncology Business Franchise of Merck KGaA, a multinational science and technology company, from July 2020 to July 2021 and served as Senior Vice President, Global Head of Oncology Business Franchise from 2019 to May 2021. Dr. Su served as Chief Medical Officer of EMD Serono, Inc., a biopharmaceutical company, from 2017 to 2019. Dr. Su also held leadership roles with increasing responsibility at Sanofi Oncology, a global healthcare company, and GSK, a global biopharmaceutical company. Before his industry career, Dr. Su served on the faculty of Duke University Medical School, where he led early oncology clinical studies focusing on mRNA-based and cell-based immunotherapy and then the University of Florida, where he was the director of the Cell and Gene Therapy program. Dr. Su has served as a member of the board of directors of Galvanize Therapeutics, Inc., a biomedical platform company, since July 2024, a member of the board of directors of CytomX Therapeutics, Inc., a public biopharmaceutical company, since March 2024 and a member of the board of directors of Marengo since July 2021. Dr. Su received his Doctor of Medicine from Technical University of Dresden in Germany and his M.B.A. from the University of Toronto in Canada. - Zhen Su，自2021年7月起担任临床阶段生物技术公司Marengo Therapeutics，Inc.（“Marengo”）的首席执行官。在加入Marengo之前，苏博士曾于2020年7月至2021年7月担任跨国科技公司默沙东 KGaA的高级副总裁兼肿瘤业务特许经营的美国&全球负责人，并于2019年至2021年5月担任高级副总裁兼肿瘤业务特许经营的全球负责人。苏博士于2017年至2019年担任生物制药公司EMD Serono，Inc.的首席医疗官。苏博士还在全球医疗保健公司赛诺菲肿瘤学和全球生物制药公司GSK担任领导职务，责任越来越大。在从事行业职业之前，苏博士曾在杜克大学医学院任职，在那里他领导了早期的肿瘤学临床研究，重点是基于mRNA和基于细胞的免疫疗法，然后是佛罗里达大学，在那里他担任细胞和基因治疗项目的主任。苏博士自2024年7月起担任生物医药平台公司Galvanize Therapeutics，Inc.的董事会成员，自2024年3月起担任上市生物制药公司CytomX医疗，Inc.的董事会成员，自2021年7月起担任Marengo的董事会成员。苏博士在德国德累斯顿工业大学获得医学博士学位，在加拿大多伦多大学获得工商管理硕士学位。
- Zhen Su,served as Chief Executive Officer of Marengo Therapeutics, Inc. ("Marengo"), a clinical-stage biotechnology company, since July 2021. Prior to joining Marengo, Dr. Su served as Senior Vice President and U.S. & Global Head of Oncology Business Franchise of Merck KGaA, a multinational science and technology company, from July 2020 to July 2021 and served as Senior Vice President, Global Head of Oncology Business Franchise from 2019 to May 2021. Dr. Su served as Chief Medical Officer of EMD Serono, Inc., a biopharmaceutical company, from 2017 to 2019. Dr. Su also held leadership roles with increasing responsibility at Sanofi Oncology, a global healthcare company, and GSK, a global biopharmaceutical company. Before his industry career, Dr. Su served on the faculty of Duke University Medical School, where he led early oncology clinical studies focusing on mRNA-based and cell-based immunotherapy and then the University of Florida, where he was the director of the Cell and Gene Therapy program. Dr. Su has served as a member of the board of directors of Galvanize Therapeutics, Inc., a biomedical platform company, since July 2024, a member of the board of directors of CytomX Therapeutics, Inc., a public biopharmaceutical company, since March 2024 and a member of the board of directors of Marengo since July 2021. Dr. Su received his Doctor of Medicine from Technical University of Dresden in Germany and his M.B.A. from the University of Toronto in Canada.
- Christy J. Oliger
-
Christy J. Oliger，曾在生物技术公司基因泰克（“Genentech”）担任多个领导职务，任职时间超过二十年，最近一次是在2017年至2020年8月期间担任肿瘤学业务部门高级副总裁，以及在2014年至2017年期间担任基因泰克神经科学和罕见病业务部门高级副总裁。在基因泰克任职期间，奥利格女士还在包括肿瘤学、神经病学、罕见病、呼吸病学、皮肤病学和免疫学在内的多个治疗领域的商业和研发领域担任过多个高级领导职务。在加入基因泰克之前，Oliger女士曾在Schering-Plough担任管理职务。Oliger女士自2024年4月起在上市生物技术公司Vera Therapeutics, Inc.的董事会任职，并担任提名和公司治理委员会成员以及商业化委员会主席。自2023年3月起，她担任上市免疫肿瘤公司LAVA Therapeutics N.V.的董事会成员，还担任审计委员会、提名和公司治理委员会成员，并自2021年12月起担任上市生物技术公司Replimune Group Inc.的董事会成员，还担任研发委员会以及薪酬委员会和指导委员会主席。Oliger女士于2021年4月至2023年9月（被Biogen Inc.收购）在上市生物制药公司Reata制药公司的董事会任职，并于2021年6月至2022年7月（被GSK PLC收购）在上市生物制药公司Sierra Oncology, Inc.的董事会任职。Oliger女士拥有加州大学圣巴巴拉分校的经济学学士学位。
Christy J. Oliger,served in numerous leadership roles over twenty years at Genentech, Inc. ("Genentech"), a biotechnology company, including most recently as Senior Vice President of the Oncology Business Unit from 2017 to August 2020, and Senior Vice President, Neuroscience and Rare Disease Business Unit at Genentech from 2014 to 2017. During her tenure with Genentech, Ms. Oliger also held a number of senior leadership roles in both commercial and research and development across a variety of therapeutic areas, including oncology, neurology, rare disease, respiratory, dermatology and immunology. Prior to Genentech, Ms. Oliger held management positions at Schering-Plough. Ms. Oliger has served on the board of directors of Vera Therapeutics, Inc., a public biotechnology company, since April 2024, where she also serves as a member of the nominating and corporate governance committee and chair of the commercialization committee. Since March 2023, she has served on the board of directors of Lava Therapeutics N.V., a public immuno-oncology company, where she also serves on the audit committee and nominating and corporate governance committee and on the board of directors of Replimune Group Inc., a public biotechnology company, since December 2021, where she also serves on the research and development committee and chair of the compensation committee and steering committee. Ms. Oliger served on the board of directors of Reata Pharmaceuticals, Inc., a public biopharmaceutical company, from April 2021 until September 2023, when it was acquired by Biogen Inc., and on the board of directors of Sierra Oncology, Inc., a public biopharmaceutical company, from June 2021 until July 2022, when it was acquired by GSK plc. Ms. Oliger holds a bachelor's degree in Economics from the University of California at Santa Barbara. - Christy J. Oliger，曾在生物技术公司基因泰克（“Genentech”）担任多个领导职务，任职时间超过二十年，最近一次是在2017年至2020年8月期间担任肿瘤学业务部门高级副总裁，以及在2014年至2017年期间担任基因泰克神经科学和罕见病业务部门高级副总裁。在基因泰克任职期间，奥利格女士还在包括肿瘤学、神经病学、罕见病、呼吸病学、皮肤病学和免疫学在内的多个治疗领域的商业和研发领域担任过多个高级领导职务。在加入基因泰克之前，Oliger女士曾在Schering-Plough担任管理职务。Oliger女士自2024年4月起在上市生物技术公司Vera Therapeutics, Inc.的董事会任职，并担任提名和公司治理委员会成员以及商业化委员会主席。自2023年3月起，她担任上市免疫肿瘤公司LAVA Therapeutics N.V.的董事会成员，还担任审计委员会、提名和公司治理委员会成员，并自2021年12月起担任上市生物技术公司Replimune Group Inc.的董事会成员，还担任研发委员会以及薪酬委员会和指导委员会主席。Oliger女士于2021年4月至2023年9月（被Biogen Inc.收购）在上市生物制药公司Reata制药公司的董事会任职，并于2021年6月至2022年7月（被GSK PLC收购）在上市生物制药公司Sierra Oncology, Inc.的董事会任职。Oliger女士拥有加州大学圣巴巴拉分校的经济学学士学位。
- Christy J. Oliger,served in numerous leadership roles over twenty years at Genentech, Inc. ("Genentech"), a biotechnology company, including most recently as Senior Vice President of the Oncology Business Unit from 2017 to August 2020, and Senior Vice President, Neuroscience and Rare Disease Business Unit at Genentech from 2014 to 2017. During her tenure with Genentech, Ms. Oliger also held a number of senior leadership roles in both commercial and research and development across a variety of therapeutic areas, including oncology, neurology, rare disease, respiratory, dermatology and immunology. Prior to Genentech, Ms. Oliger held management positions at Schering-Plough. Ms. Oliger has served on the board of directors of Vera Therapeutics, Inc., a public biotechnology company, since April 2024, where she also serves as a member of the nominating and corporate governance committee and chair of the commercialization committee. Since March 2023, she has served on the board of directors of Lava Therapeutics N.V., a public immuno-oncology company, where she also serves on the audit committee and nominating and corporate governance committee and on the board of directors of Replimune Group Inc., a public biotechnology company, since December 2021, where she also serves on the research and development committee and chair of the compensation committee and steering committee. Ms. Oliger served on the board of directors of Reata Pharmaceuticals, Inc., a public biopharmaceutical company, from April 2021 until September 2023, when it was acquired by Biogen Inc., and on the board of directors of Sierra Oncology, Inc., a public biopharmaceutical company, from June 2021 until July 2022, when it was acquired by GSK plc. Ms. Oliger holds a bachelor's degree in Economics from the University of California at Santa Barbara.
- Barry E. Greene
-
Barry E. Greene，2013年1月以来，他担任董事会成员。2007年以来，他担任Alnylam Pharmaceuticals, Inc.（一个上市的生物制药公司）的总裁和首席运营官。2003年以来，他担任其首席运营官。从2004年到2005年，他担任其财务主管。加入Alnylam之前，他曾是千年制药公司（Millennium Pharmaceuticals）的肿瘤总经理。他领导公司的肿瘤业务的全球战略和行政，包括战略业务方向和执行，最终成功获得食品及药物管理局（FDA）批准和万珂（VELCADE bortezomib）的发行（2003年中期）。2001年加入Millennium之前，他担任Mediconsult.com（医疗咨询公司）的执行副总裁和首席商务官。加入Mediconsult.com之前，他的经验包括担任AstraZeneca （原AstraMerck，生物制药公司）市场营销和客户服务副总裁、AstraZeneca North American的战略集成副总裁、安信达咨询公司（Andersen Consulting，咨询公司）的合伙人负责制药/生物技术市场和销售实践。他目前担任Acorda Therapeutics, Inc.（一个上市的生物制药公司）的董事会成员。他获得Pittsburgh大学的工业管理学学士学位并担任杜克大学（ Duke University ）福夸商学院（Fuqua School of Business）的高级进修生。
Barry E. Greene,has served as Chief Executive Officer of Sage Therapeutics, Inc. ("Sage"), a public biopharmaceutical company, since December 2020. Mr. Greene served as President of Alnylam Pharmaceuticals, Inc. ("Alnylam"), a public biopharmaceutical company, from 2007 to September 2020, and as its Chief Operating Officer from 2003 to 2016. Prior to Alnylam, he was General Manager of Oncology at Millennium Pharmaceuticals, Inc. ("Millennium"), a public biopharmaceutical company. Prior to joining Millennium in 2001, Mr. Greene served as Executive Vice President and Chief Business Officer for Mediconsult.com. Prior to Mediconsult.com, Mr. Greene's experience included serving as Vice President of Marketing and Customer Services for AstraZeneca (formerly AstraMerck), a public biopharmaceutical company; Vice President, Strategic Integration with responsibility for the AstraZeneca North American post-merger integration; and a partner of Andersen Consulting. Mr. Greene has served as a member of the board of directors of Sage since October 2020. Mr. Greene served as a member of the board of directors of BCLS Acquisition Corp., a special purpose acquisition company, from October 2020 to October 2022. From 2007 to August 2021, Mr. Greene served as a member of the board of directors of Acorda Therapeutics, Inc., a public biopharmaceutical company, where he also served as a member of its compensation committee. Mr. Greene received his B.S. in Industrial Engineering from the University of Pittsburgh and served as a Senior Scholar at Duke University's Fuqua School of Business. - Barry E. Greene，2013年1月以来，他担任董事会成员。2007年以来，他担任Alnylam Pharmaceuticals, Inc.（一个上市的生物制药公司）的总裁和首席运营官。2003年以来，他担任其首席运营官。从2004年到2005年，他担任其财务主管。加入Alnylam之前，他曾是千年制药公司（Millennium Pharmaceuticals）的肿瘤总经理。他领导公司的肿瘤业务的全球战略和行政，包括战略业务方向和执行，最终成功获得食品及药物管理局（FDA）批准和万珂（VELCADE bortezomib）的发行（2003年中期）。2001年加入Millennium之前，他担任Mediconsult.com（医疗咨询公司）的执行副总裁和首席商务官。加入Mediconsult.com之前，他的经验包括担任AstraZeneca （原AstraMerck，生物制药公司）市场营销和客户服务副总裁、AstraZeneca North American的战略集成副总裁、安信达咨询公司（Andersen Consulting，咨询公司）的合伙人负责制药/生物技术市场和销售实践。他目前担任Acorda Therapeutics, Inc.（一个上市的生物制药公司）的董事会成员。他获得Pittsburgh大学的工业管理学学士学位并担任杜克大学（ Duke University ）福夸商学院（Fuqua School of Business）的高级进修生。
- Barry E. Greene,has served as Chief Executive Officer of Sage Therapeutics, Inc. ("Sage"), a public biopharmaceutical company, since December 2020. Mr. Greene served as President of Alnylam Pharmaceuticals, Inc. ("Alnylam"), a public biopharmaceutical company, from 2007 to September 2020, and as its Chief Operating Officer from 2003 to 2016. Prior to Alnylam, he was General Manager of Oncology at Millennium Pharmaceuticals, Inc. ("Millennium"), a public biopharmaceutical company. Prior to joining Millennium in 2001, Mr. Greene served as Executive Vice President and Chief Business Officer for Mediconsult.com. Prior to Mediconsult.com, Mr. Greene's experience included serving as Vice President of Marketing and Customer Services for AstraZeneca (formerly AstraMerck), a public biopharmaceutical company; Vice President, Strategic Integration with responsibility for the AstraZeneca North American post-merger integration; and a partner of Andersen Consulting. Mr. Greene has served as a member of the board of directors of Sage since October 2020. Mr. Greene served as a member of the board of directors of BCLS Acquisition Corp., a special purpose acquisition company, from October 2020 to October 2022. From 2007 to August 2021, Mr. Greene served as a member of the board of directors of Acorda Therapeutics, Inc., a public biopharmaceutical company, where he also served as a member of its compensation committee. Mr. Greene received his B.S. in Industrial Engineering from the University of Pittsburgh and served as a Senior Scholar at Duke University's Fuqua School of Business.
- Deepa R. Pakianathan
-
Deepa R. Pakianathan，她担任董事会的董事（2008年12月以来）。自2001年以来，她担任特尔斐投资公司（Delphi Ventures）（一个专注于医疗器械和生物技术投资的风险资本公司）的管理成员并且领导公司的生物技术投资活动。加入特尔斐投资公司（Delphi Ventures）之前，她担任摩根大通公司（JP Morgan）的医疗部门的副总裁。自2004年以来，她在Alexza Pharmaceuticals, Inc.（一个上市的制药公司）的董事会任职。在那里，她担任其薪酬委员会和提名和治理委员会的成员。她此前在PTC Therapeutics, Inc.（一个上市的制药公司）和Relypsa, Inc.（一个上市的制药公司）的董事会任职。她获得印度Bombay大学的学士学位、Bombay大学癌症研究所的硕士学位和Wake Forest大学的硕士和博士学位。
Deepa R. Pakianathan,was a senior biotechnology banker at JPMorgan, a global investment bank, from 1997 to 1998, she was a research analyst covering biotechnology at Genesis Merchant Group Securities and from 1993 to 1997 she was a post-doctoral research scientist at Genentech. Dr. Pakianathan has served on the board of directors of Theravance Biopharma, Inc., a public biopharmaceutical company, since July 2020, where she also serves as chair of the nominating and governance committee and a member of the audit committee and the development and commercialization committee, and Mereo Biopharma Group PLC, a public biopharmaceutical company, since 2019, where she also serves as chair of its audit committee and a member of the remuneration committee. In December 2020, Dr. Pakianathan was appointed to the board of directors of Palleon Pharmaceuticals, Inc., a biotechnology company, where she serves as lead director and chair of the audit committee and the compensation committee. In January 2021, Dr. Pakianathan was appointed to the board of Freenome Holdings, Inc., a diagnostic company, where she serves as chair of the audit committee and a member of the compensation committee. From August 2020 to February 2021, Dr. Pakianathan served on the board of directors of Foresite Development Corp I, and from February 2021 to December 2021, Dr. Pakianathan served on the board of directors of Foresite Development Corp II, both public special purpose acquisition companies. Dr. Pakianathan also served on the board of directors of Calithera Biosciences, Inc., a public biopharmaceutical company, from 2010 to December 2023; the board of directors of Alder Biopharmaceuticals, Inc., a public biopharmaceutical company, from 2007 until 2019, when it was acquired by Lundbeck A/S; the board of directors of OncoMed Pharmaceuticals, Inc., a public biopharmaceutical company, from 2008 until 2019, when it was acquired by Mereo Biopharma Group PLC; and the board of directors of Alexza Pharmaceuticals, Inc., a public biopharmaceutical company, from 2004 to 2016. Dr. Pakianathan holds a M.S. and Ph.D. from Wake Forest University, a B.Sc. from the University of Bombay, India and a M.Sc. from The Cancer Research Institute at the University of Bombay, India. - Deepa R. Pakianathan，她担任董事会的董事（2008年12月以来）。自2001年以来，她担任特尔斐投资公司（Delphi Ventures）（一个专注于医疗器械和生物技术投资的风险资本公司）的管理成员并且领导公司的生物技术投资活动。加入特尔斐投资公司（Delphi Ventures）之前，她担任摩根大通公司（JP Morgan）的医疗部门的副总裁。自2004年以来，她在Alexza Pharmaceuticals, Inc.（一个上市的制药公司）的董事会任职。在那里，她担任其薪酬委员会和提名和治理委员会的成员。她此前在PTC Therapeutics, Inc.（一个上市的制药公司）和Relypsa, Inc.（一个上市的制药公司）的董事会任职。她获得印度Bombay大学的学士学位、Bombay大学癌症研究所的硕士学位和Wake Forest大学的硕士和博士学位。
- Deepa R. Pakianathan,was a senior biotechnology banker at JPMorgan, a global investment bank, from 1997 to 1998, she was a research analyst covering biotechnology at Genesis Merchant Group Securities and from 1993 to 1997 she was a post-doctoral research scientist at Genentech. Dr. Pakianathan has served on the board of directors of Theravance Biopharma, Inc., a public biopharmaceutical company, since July 2020, where she also serves as chair of the nominating and governance committee and a member of the audit committee and the development and commercialization committee, and Mereo Biopharma Group PLC, a public biopharmaceutical company, since 2019, where she also serves as chair of its audit committee and a member of the remuneration committee. In December 2020, Dr. Pakianathan was appointed to the board of directors of Palleon Pharmaceuticals, Inc., a biotechnology company, where she serves as lead director and chair of the audit committee and the compensation committee. In January 2021, Dr. Pakianathan was appointed to the board of Freenome Holdings, Inc., a diagnostic company, where she serves as chair of the audit committee and a member of the compensation committee. From August 2020 to February 2021, Dr. Pakianathan served on the board of directors of Foresite Development Corp I, and from February 2021 to December 2021, Dr. Pakianathan served on the board of directors of Foresite Development Corp II, both public special purpose acquisition companies. Dr. Pakianathan also served on the board of directors of Calithera Biosciences, Inc., a public biopharmaceutical company, from 2010 to December 2023; the board of directors of Alder Biopharmaceuticals, Inc., a public biopharmaceutical company, from 2007 until 2019, when it was acquired by Lundbeck A/S; the board of directors of OncoMed Pharmaceuticals, Inc., a public biopharmaceutical company, from 2008 until 2019, when it was acquired by Mereo Biopharma Group PLC; and the board of directors of Alexza Pharmaceuticals, Inc., a public biopharmaceutical company, from 2004 to 2016. Dr. Pakianathan holds a M.S. and Ph.D. from Wake Forest University, a B.Sc. from the University of Bombay, India and a M.Sc. from The Cancer Research Institute at the University of Bombay, India.
- Chen Schor
-
Chen Schor，自2016年起担任resTORbio， Inc.的总裁兼首席执行官，直到2020年9月与Adicet Bio合并。在加入resTORbio之前，Schor先生从2014年到2016年担任Synta Pharmaceuticals Corporation的总裁、首席执行官和董事。此前，他曾担任Teva Pharmaceuticals Industries Ltd.的全球品牌业务发展和管道管理副总裁，并在几家新兴的私人和上市公司担任领导职务。在此之前，他是Yozma Venture Capital的合伙人，在那里他领导了多家治疗公司从成立到商业成功的基础和发展。他曾担任resTORbio/Adicet Bio的董事会成员（2016年以来），也曾担任Brainstorm Cell Therapeutics Inc.（上市生物技术公司）的董事会成员和审计委员会成员（2011年至2020年）。他领导了价值超过80亿美元的战略交易，包括GlaxoSmithKline plc、Amgen Inc.、Pfizer、Merck KGaA（共同领导）和Cephalon， Inc.（共同领导）。他持有Tel Aviv大学的生物学学士学位和工商管理硕士学位，以及Haifa大学的经济学和会计学学士学位，他是一名注册会计师。
Chen Schor,held the role of President and Chief Executive Officer at resTORbio, Inc. ("resTORbio") from 2016 until its merger with Adicet Bio in September 2020. Prior to resTORbio, Mr. Schor served as President, Chief Executive Officer and Director of Synta Pharmaceuticals Corporation from 2014 until 2016. Previously, he served as Vice President, Global Branded Business Development and Pipeline Management at Teva Pharmaceuticals Industries Ltd. and held leadership positions at several emerging private and public companies. Before that, Mr. Schor was a Partner at Yozma Venture Capital, where he led the foundation and growth of multiple therapeutic companies from inception to commercial success. Mr. Schor has served on the board of directors of resTORbio/Adicet Bio since 2016 and also served on the board of directors and audit committee of Brainstorm Cell Therapeutics Inc., a public biotechnology company, from 2011 until 2020. Mr. Schor has led strategic transactions valued at over $8 billion with companies such as GlaxoSmithKline plc, Amgen Inc., Pfizer, Merck KGaA (co-led) and Cephalon, Inc. (co-led). Mr. Schor holds a B.A. in Biology and an M.B.A. from Tel Aviv University, a B.A. in Economics and Accounting from Haifa University and is a Certified Public Accountant. - Chen Schor，自2016年起担任resTORbio， Inc.的总裁兼首席执行官，直到2020年9月与Adicet Bio合并。在加入resTORbio之前，Schor先生从2014年到2016年担任Synta Pharmaceuticals Corporation的总裁、首席执行官和董事。此前，他曾担任Teva Pharmaceuticals Industries Ltd.的全球品牌业务发展和管道管理副总裁，并在几家新兴的私人和上市公司担任领导职务。在此之前，他是Yozma Venture Capital的合伙人，在那里他领导了多家治疗公司从成立到商业成功的基础和发展。他曾担任resTORbio/Adicet Bio的董事会成员（2016年以来），也曾担任Brainstorm Cell Therapeutics Inc.（上市生物技术公司）的董事会成员和审计委员会成员（2011年至2020年）。他领导了价值超过80亿美元的战略交易，包括GlaxoSmithKline plc、Amgen Inc.、Pfizer、Merck KGaA（共同领导）和Cephalon， Inc.（共同领导）。他持有Tel Aviv大学的生物学学士学位和工商管理硕士学位，以及Haifa大学的经济学和会计学学士学位，他是一名注册会计师。
- Chen Schor,held the role of President and Chief Executive Officer at resTORbio, Inc. ("resTORbio") from 2016 until its merger with Adicet Bio in September 2020. Prior to resTORbio, Mr. Schor served as President, Chief Executive Officer and Director of Synta Pharmaceuticals Corporation from 2014 until 2016. Previously, he served as Vice President, Global Branded Business Development and Pipeline Management at Teva Pharmaceuticals Industries Ltd. and held leadership positions at several emerging private and public companies. Before that, Mr. Schor was a Partner at Yozma Venture Capital, where he led the foundation and growth of multiple therapeutic companies from inception to commercial success. Mr. Schor has served on the board of directors of resTORbio/Adicet Bio since 2016 and also served on the board of directors and audit committee of Brainstorm Cell Therapeutics Inc., a public biotechnology company, from 2011 until 2020. Mr. Schor has led strategic transactions valued at over $8 billion with companies such as GlaxoSmithKline plc, Amgen Inc., Pfizer, Merck KGaA (co-led) and Cephalon, Inc. (co-led). Mr. Schor holds a B.A. in Biology and an M.B.A. from Tel Aviv University, a B.A. in Economics and Accounting from Haifa University and is a Certified Public Accountant.
- Garen G. Bohlin
-
Garen G. Bohlin，从2013年10月开始担任公司董事会成员。从2012年4月开始，他一直专注服务于董事和咨询委员会。 从2010年1月到2012年4月他退休期间，他担任Constellation 制药公司（Constellation Pharmaceuticals, Inc.）执行副总裁，这是一家生物制药公司，他在那里的职责是完善从挑选到采购的流程和先前谈判的与Genentech的合并条款。在加入 Constellation 制药公司（Constellation Pharmaceuticals, Inc.）之前，他在Sirtris 制药公司（Sirtris Pharmaceuticals）担任首席运营官，这是一家生物科技公司，从2006年1月到2009年12月，他在Sirtris 制药公司（Sirtris Pharmaceuticals）整体管理方面、首次公开发行和公司向葛兰素史克公司（GlaxoSmithKline）销售方面发挥重要作用。从1999年到2008年12月，他是Syntonix 制药公司（Syntonix Pharmaceuticals, Inc.）的创始首席执行官，这是一家生物制药公司，在那里他在整体管理方面、最终销售到Biogen Idec的定位方面都发挥了重要作用。 在加入Syntonix 制药公司（Syntonix Pharmaceuticals, Inc.）之前，他是遗传学研究所有限公司（Genetics Institute Inc.）执行副总裁，这是一家生物科技公司，在那里他在整体管理方面、首次公开发行、向美国家用产品/惠氏销售方面发挥重要作用，并且他是公共会计和咨询机构——安达信公司的合伙人。他在Tetraphase 制药公司（Tetraphase Pharmaceuticals, Inc.）和Acusphere 公司（Acusphere, Inc.）担任董事会和审计委员会成员，两者都是上市的生物制药公司；在Precision皮肤科有限公司（Precision Dermatology, Inc.）担任董事会和审计委员会成员，这是一家私营的生物科技公司。Bohlin先生持有Illinois大学的会计学士学位。
Garen G. Bohlin,has focused exclusively on service on boards of directors and consulting. From 2010 until his retirement in 2012, he served as Executive Vice President of Constellation Pharmaceuticals, Inc. ("Constellation"), a biopharmaceutical company, which was private at that time. Prior to Constellation, Mr. Bohlin served as Chief Operating Officer of Sirtris Pharmaceuticals, Inc., from 2006 to 2009, which was acquired by GlaxoSmithKline plc. From 1999 through 2008, Mr. Bohlin served as President and Chief Executive Officer of Syntonix Pharmaceuticals, Inc. ("Syntonix"), which was acquired by Biogen Idec. Prior to Syntonix, Mr. Bohlin spent 14 years in executive management at Genetics Institute, Inc., which was acquired by Wyeth, and prior to that he was a partner at Arthur Andersen & Co., where he spent 13 years. Mr. Bohlin has served on the board of directors of Collegium Pharmaceutical, Inc., a public specialty pharmaceutical company, since 2015, where he also serves on the audit committee and compensation committee, and as Chairman of the board of directors of Curadel Surgical Innovations, Inc., a medical imaging company, since 2020. Mr. Bohlin previously served on the board of directors of Proteon Therapeutics, Inc., a public biopharmaceutical company, from 2014 through 2020, where he also served on the audit committee, compensation committee and nominating and corporate governance committee. He also previously served on the board of directors of Tetraphase Pharmaceuticals, Inc., a public biotechnology company, from 2010 through July 2020, where he also served on the audit committee. Mr. Bohlin holds a B.S. in Accounting from the University of Illinois. - Garen G. Bohlin，从2013年10月开始担任公司董事会成员。从2012年4月开始，他一直专注服务于董事和咨询委员会。 从2010年1月到2012年4月他退休期间，他担任Constellation 制药公司（Constellation Pharmaceuticals, Inc.）执行副总裁，这是一家生物制药公司，他在那里的职责是完善从挑选到采购的流程和先前谈判的与Genentech的合并条款。在加入 Constellation 制药公司（Constellation Pharmaceuticals, Inc.）之前，他在Sirtris 制药公司（Sirtris Pharmaceuticals）担任首席运营官，这是一家生物科技公司，从2006年1月到2009年12月，他在Sirtris 制药公司（Sirtris Pharmaceuticals）整体管理方面、首次公开发行和公司向葛兰素史克公司（GlaxoSmithKline）销售方面发挥重要作用。从1999年到2008年12月，他是Syntonix 制药公司（Syntonix Pharmaceuticals, Inc.）的创始首席执行官，这是一家生物制药公司，在那里他在整体管理方面、最终销售到Biogen Idec的定位方面都发挥了重要作用。 在加入Syntonix 制药公司（Syntonix Pharmaceuticals, Inc.）之前，他是遗传学研究所有限公司（Genetics Institute Inc.）执行副总裁，这是一家生物科技公司，在那里他在整体管理方面、首次公开发行、向美国家用产品/惠氏销售方面发挥重要作用，并且他是公共会计和咨询机构——安达信公司的合伙人。他在Tetraphase 制药公司（Tetraphase Pharmaceuticals, Inc.）和Acusphere 公司（Acusphere, Inc.）担任董事会和审计委员会成员，两者都是上市的生物制药公司；在Precision皮肤科有限公司（Precision Dermatology, Inc.）担任董事会和审计委员会成员，这是一家私营的生物科技公司。Bohlin先生持有Illinois大学的会计学士学位。
- Garen G. Bohlin,has focused exclusively on service on boards of directors and consulting. From 2010 until his retirement in 2012, he served as Executive Vice President of Constellation Pharmaceuticals, Inc. ("Constellation"), a biopharmaceutical company, which was private at that time. Prior to Constellation, Mr. Bohlin served as Chief Operating Officer of Sirtris Pharmaceuticals, Inc., from 2006 to 2009, which was acquired by GlaxoSmithKline plc. From 1999 through 2008, Mr. Bohlin served as President and Chief Executive Officer of Syntonix Pharmaceuticals, Inc. ("Syntonix"), which was acquired by Biogen Idec. Prior to Syntonix, Mr. Bohlin spent 14 years in executive management at Genetics Institute, Inc., which was acquired by Wyeth, and prior to that he was a partner at Arthur Andersen & Co., where he spent 13 years. Mr. Bohlin has served on the board of directors of Collegium Pharmaceutical, Inc., a public specialty pharmaceutical company, since 2015, where he also serves on the audit committee and compensation committee, and as Chairman of the board of directors of Curadel Surgical Innovations, Inc., a medical imaging company, since 2020. Mr. Bohlin previously served on the board of directors of Proteon Therapeutics, Inc., a public biopharmaceutical company, from 2014 through 2020, where he also served on the audit committee, compensation committee and nominating and corporate governance committee. He also previously served on the board of directors of Tetraphase Pharmaceuticals, Inc., a public biotechnology company, from 2010 through July 2020, where he also served on the audit committee. Mr. Bohlin holds a B.S. in Accounting from the University of Illinois.
高管简历
中英对照 | 中文 | 英文- Reshma Rangwala
Reshma Rangwala自2020年9月28日起担任我们的首席医疗官。此前，从2017年5月到2020年7月，她曾担任Genmab Inc.的医学副总裁，在那里她领导了一流抗体药物偶联物的临床开发计划，并管理临床战略，协议开发，数据监控，数据分析，研究报告撰写，生物许可申请准备。从2012年6月到2017年5月，Rangwala博士担任Merck&Co的执行临床主任，在那里她参与了Keytruda在非小细胞肺癌和妇科恶性肿瘤的临床开发。她在杜克大学（Duke University）获得生物学学士学位，在辛辛那提大学医学院（University of Cincinnati College of Medicine）获得医学博士学位。她在密苏里州圣路易斯的巴恩斯犹太医院完成了内科住院治疗，并在宾夕法尼亚大学医院完成了肿瘤医学奖学金。
Reshma Rangwala,joined Karyopharm in April 2022 as Executive Vice President, Chief Medical Officer, with more than a decade of experience in oncology and drug development. Dr. Rangwala served as Chief Medical Officer of Aravive, Inc., a public oncology company, from September 2020 to April 2022. Prior to that, Dr. Rangwala served as Vice President, Medical, at Genmab Inc., an international biotechnology company, from 2017 to July 2020. Prior to that, Dr. Rangwala served as Executive Clinical Director at Merck & Co., a biopharmaceutical company, from 2012 to 2017. Dr. Rangwala received her B.S. in Biology from Duke University and her M.D./Ph.D. from the University of Cincinnati College of Medicine. She completed her internal medicine residency at Barnes Jewish Hospital in St. Louis, Missouri and her medical oncology fellowship at the Hospital of the University of Pennsylvania.- Reshma Rangwala自2020年9月28日起担任我们的首席医疗官。此前，从2017年5月到2020年7月，她曾担任Genmab Inc.的医学副总裁，在那里她领导了一流抗体药物偶联物的临床开发计划，并管理临床战略，协议开发，数据监控，数据分析，研究报告撰写，生物许可申请准备。从2012年6月到2017年5月，Rangwala博士担任Merck&Co的执行临床主任，在那里她参与了Keytruda在非小细胞肺癌和妇科恶性肿瘤的临床开发。她在杜克大学（Duke University）获得生物学学士学位，在辛辛那提大学医学院（University of Cincinnati College of Medicine）获得医学博士学位。她在密苏里州圣路易斯的巴恩斯犹太医院完成了内科住院治疗，并在宾夕法尼亚大学医院完成了肿瘤医学奖学金。
- Reshma Rangwala,joined Karyopharm in April 2022 as Executive Vice President, Chief Medical Officer, with more than a decade of experience in oncology and drug development. Dr. Rangwala served as Chief Medical Officer of Aravive, Inc., a public oncology company, from September 2020 to April 2022. Prior to that, Dr. Rangwala served as Vice President, Medical, at Genmab Inc., an international biotechnology company, from 2017 to July 2020. Prior to that, Dr. Rangwala served as Executive Clinical Director at Merck & Co., a biopharmaceutical company, from 2012 to 2017. Dr. Rangwala received her B.S. in Biology from Duke University and her M.D./Ph.D. from the University of Cincinnati College of Medicine. She completed her internal medicine residency at Barnes Jewish Hospital in St. Louis, Missouri and her medical oncology fellowship at the Hospital of the University of Pennsylvania.
- Lori Macomber
Lori Macomber，自2021年3月起担任传奇生物技术公司财务副总裁，Macomber女士担任传奇生物技术公司首席财务官和首席会计官。Macomber女士自2019年9月起担任传奇生物技术公司供应链财务副总裁兼财务总监。在加入传奇生物技术公司之前，Macomber女士于2018年3月至2019年9月担任阿美特克PDS的业务部门总监，该公司是航空航天和国防工业组件和系统的领先供应商，并于2017年4月至2018年2月担任Cello Health的美国首席财务官和总监。在此之前，Macomber女士曾在礼来公司担任过多个职位，最近担任财务网站副总裁，从2010年5月到2017年4月任职于该公司。Macomber女士拥有宾夕法尼亚州立大学会计学学士学位，是一名注册会计师。
Lori Macomber,has served as Legend Biotech Corporation vice president, finance, since March 2021, in which capacity Ms. Macomber serves as Legend Biotech Corporation principal financial officer and principal accounting officer. Ms. Macomber has served as Legend Biotech Corporation vice president of supply chain finance and controller since September 2019. Prior to joining Legend Biotech Corporation , Ms. Macomber served as Business Unit Controller at Ametek PDS, a leading supplier of components and systems for the aerospace and defense industries, from March 2018 to September 2019 and as U.S. CFO and Controller of Cello Health from April 2017 until February 2018. Before this Ms. Macomber held various positions, most recently AVP Finance Site Leader, at Eli Lilly & Company where she was employed from May 2010 until April 2017. Ms. Macomber holds a Bachelor of Science in Accounting from Pennsylvania State University and is a Certified Public Accountant.- Lori Macomber，自2021年3月起担任传奇生物技术公司财务副总裁，Macomber女士担任传奇生物技术公司首席财务官和首席会计官。Macomber女士自2019年9月起担任传奇生物技术公司供应链财务副总裁兼财务总监。在加入传奇生物技术公司之前，Macomber女士于2018年3月至2019年9月担任阿美特克PDS的业务部门总监，该公司是航空航天和国防工业组件和系统的领先供应商，并于2017年4月至2018年2月担任Cello Health的美国首席财务官和总监。在此之前，Macomber女士曾在礼来公司担任过多个职位，最近担任财务网站副总裁，从2010年5月到2017年4月任职于该公司。Macomber女士拥有宾夕法尼亚州立大学会计学学士学位，是一名注册会计师。
- Lori Macomber,has served as Legend Biotech Corporation vice president, finance, since March 2021, in which capacity Ms. Macomber serves as Legend Biotech Corporation principal financial officer and principal accounting officer. Ms. Macomber has served as Legend Biotech Corporation vice president of supply chain finance and controller since September 2019. Prior to joining Legend Biotech Corporation , Ms. Macomber served as Business Unit Controller at Ametek PDS, a leading supplier of components and systems for the aerospace and defense industries, from March 2018 to September 2019 and as U.S. CFO and Controller of Cello Health from April 2017 until February 2018. Before this Ms. Macomber held various positions, most recently AVP Finance Site Leader, at Eli Lilly & Company where she was employed from May 2010 until April 2017. Ms. Macomber holds a Bachelor of Science in Accounting from Pennsylvania State University and is a Certified Public Accountant.
- Richard Paulson
Richard Paulson，自2023年起在bluebird bio, Inc.董事会任职。自2021年以来，鲍尔森先生一直担任商业阶段制药公司Karyopharm Therapeutics的总裁、首席执行官兼董事。此前，Paulson先生曾于2018年至2021年担任Ipsen Pharmaceuticals执行副总裁兼Ipsen North America首席执行官，专注于肿瘤学、神经科学和罕见病的创新疗法和专科护理。在加入益普生之前，保尔森先生在安进工作了10年，在欧洲和北美担任过多个领导职务。保尔森先生获得了多伦多大学的工商管理硕士学位和萨斯喀彻温大学的市场营销和金融学士学位。
Richard Paulson,has served on Bluebird Bio, Inc. Board since 2023. Since 2021, Mr. Paulson has been President, Chief Executive Officer and Director at Karyopharm Therapeutics, a commercial-stage pharmaceutical company. Previously, Mr. Paulson was Executive Vice President of Ipsen Pharmaceuticals and Chief Executive Officer of Ipsen North America from 2018 to 2021 where he focused on innovative therapies and specialty care for oncology, neuroscience and rare diseases. Before joining Ipsen, Mr. Paulson work at Amgen for 10 years holding various leadership positions across Europe and North America. Mr. Paulson received his M.B.A. from the University of Toronto and his B.Com in marketing and finance from the University of Saskatchewan.- Richard Paulson，自2023年起在bluebird bio, Inc.董事会任职。自2021年以来，鲍尔森先生一直担任商业阶段制药公司Karyopharm Therapeutics的总裁、首席执行官兼董事。此前，Paulson先生曾于2018年至2021年担任Ipsen Pharmaceuticals执行副总裁兼Ipsen North America首席执行官，专注于肿瘤学、神经科学和罕见病的创新疗法和专科护理。在加入益普生之前，保尔森先生在安进工作了10年，在欧洲和北美担任过多个领导职务。保尔森先生获得了多伦多大学的工商管理硕士学位和萨斯喀彻温大学的市场营销和金融学士学位。
- Richard Paulson,has served on Bluebird Bio, Inc. Board since 2023. Since 2021, Mr. Paulson has been President, Chief Executive Officer and Director at Karyopharm Therapeutics, a commercial-stage pharmaceutical company. Previously, Mr. Paulson was Executive Vice President of Ipsen Pharmaceuticals and Chief Executive Officer of Ipsen North America from 2018 to 2021 where he focused on innovative therapies and specialty care for oncology, neuroscience and rare diseases. Before joining Ipsen, Mr. Paulson work at Amgen for 10 years holding various leadership positions across Europe and North America. Mr. Paulson received his M.B.A. from the University of Toronto and his B.Com in marketing and finance from the University of Saskatchewan.
- Sohanya Cheng
Sohanya Cheng，自2024年10月起担任Carisma董事会成员。Cheng女士目前担任Karyopharm Therapeutics Inc.（纳斯达克：KPTI）（“Karyopharm”）的执行副总裁、首席商务官和业务发展主管，该公司是一家上市制药公司，自2021年12月起担任该公司的执行副总裁、首席商务官和业务发展主管，此前曾于2021年6月至2021年12月担任销售和商业运营高级副总裁。在加入Karyopharm之前，程女士于2020年8月至2020年12月在Arrowhead Pharmaceuticals, Inc.（纳斯达克：ARWR）（“Arrowhead”）一家上市制药公司担任副总裁、市场营销和公司事务主管。在任职Arrowhead之前，程女士曾在上市生物技术公司安进工作了11年，在那里她担任过各种销售和营销领导职务，支持关键肿瘤品牌的商业化，包括2019年至2020年8月担任执行董事、全国销售队伍和肿瘤承包战略负责人，2018年至2019年担任多发性骨髓瘤业务执行董事、营销和销售负责人，2017年至2018年担任肿瘤业务参谋长至总经理兼战略与运营总监。程女士拥有麻省理工学院斯隆管理学院的MBA学位以及英国剑桥大学的理学学士和硕士学位。
Sohanya Cheng,has served as a member of Carisma's board of directors since October 2024. Ms. Cheng currently serves as the EVP, Chief Commercial Officer, and Head of Business Development at Karyopharm Therapeutics Inc. (Nasdaq: KPTI) ("Karyopharm"), a public pharmaceutical company, since December 2021 and was previously the SVP, Sales and Commercial Operations from June 2021 to December 2021. Prior to joining Karyopharm, Ms. Cheng was Vice President, Head of Marketing and Corporate Affairs at Arrowhead Pharmaceuticals, Inc. (Nasdaq: ARWR) ("Arrowhead"), a public pharmaceutical company, from August 2020 to December 2020. Prior to her role at Arrowhead, Ms. Cheng spent 11 years at Amgen, a public biotechnology company, where she held a variety of sales and marketing leadership roles supporting the commercialization of key oncology brands, including as Executive Director, Head of National Sales Force & Oncology Contracting Strategy from 2019 to August 2020, Executive Director, Head of Marketing & Sales for their multiple myeloma business from 2018 to 2019, and Chief of Staff to General Manager and Strategy & Operations Director for their oncology business from 2017 to 2018. Ms. Cheng holds a MBA from the MIT Sloan School of Management and both a BSc and MA from the University of Cambridge, UK.- Sohanya Cheng，自2024年10月起担任Carisma董事会成员。Cheng女士目前担任Karyopharm Therapeutics Inc.（纳斯达克：KPTI）（“Karyopharm”）的执行副总裁、首席商务官和业务发展主管，该公司是一家上市制药公司，自2021年12月起担任该公司的执行副总裁、首席商务官和业务发展主管，此前曾于2021年6月至2021年12月担任销售和商业运营高级副总裁。在加入Karyopharm之前，程女士于2020年8月至2020年12月在Arrowhead Pharmaceuticals, Inc.（纳斯达克：ARWR）（“Arrowhead”）一家上市制药公司担任副总裁、市场营销和公司事务主管。在任职Arrowhead之前，程女士曾在上市生物技术公司安进工作了11年，在那里她担任过各种销售和营销领导职务，支持关键肿瘤品牌的商业化，包括2019年至2020年8月担任执行董事、全国销售队伍和肿瘤承包战略负责人，2018年至2019年担任多发性骨髓瘤业务执行董事、营销和销售负责人，2017年至2018年担任肿瘤业务参谋长至总经理兼战略与运营总监。程女士拥有麻省理工学院斯隆管理学院的MBA学位以及英国剑桥大学的理学学士和硕士学位。
- Sohanya Cheng,has served as a member of Carisma's board of directors since October 2024. Ms. Cheng currently serves as the EVP, Chief Commercial Officer, and Head of Business Development at Karyopharm Therapeutics Inc. (Nasdaq: KPTI) ("Karyopharm"), a public pharmaceutical company, since December 2021 and was previously the SVP, Sales and Commercial Operations from June 2021 to December 2021. Prior to joining Karyopharm, Ms. Cheng was Vice President, Head of Marketing and Corporate Affairs at Arrowhead Pharmaceuticals, Inc. (Nasdaq: ARWR) ("Arrowhead"), a public pharmaceutical company, from August 2020 to December 2020. Prior to her role at Arrowhead, Ms. Cheng spent 11 years at Amgen, a public biotechnology company, where she held a variety of sales and marketing leadership roles supporting the commercialization of key oncology brands, including as Executive Director, Head of National Sales Force & Oncology Contracting Strategy from 2019 to August 2020, Executive Director, Head of Marketing & Sales for their multiple myeloma business from 2018 to 2019, and Chief of Staff to General Manager and Strategy & Operations Director for their oncology business from 2017 to 2018. Ms. Cheng holds a MBA from the MIT Sloan School of Management and both a BSc and MA from the University of Cambridge, UK.
- Michael Mano
Michael Mano，于2020年12月加入Karyopharm，担任高级副总裁、总法律顾问和秘书，拥有超过15年的法律经验。在加入Karyopharm之前，Mano先生曾于2018年1月至2020年12月担任上市生物技术公司渤健业务发展方面的法律顾问，在那里他支持渤健的全球业务发展平台。在此之前，他于2013年至2018年担任国际律师事务所Proskauer Rose LLP的高级法律顾问，在那里他代表客户处理广泛的公司事务。在加入Proskauer Rose LLP之前，Mano先生从事私人法律业务，在那里他代表生命科学行业的客户处理广泛的公司事务。Mano先生在圣迈克尔学院获得政治学和社会学学士学位，在华盛顿大学法学院获得法学博士学位。
Michael Mano,joined Karyopharm as Senior Vice President, General Counsel and Secretary in December 2020 with over 15 years of legal experience. Prior to joining Karyopharm, Mr. Mano served as Counsel, Business Development for Biogen, a public biotechnology company, from January 2018 to December 2020, where he supported Biogen's global business development platform. Prior to that he was Senior Counsel at Proskauer Rose LLP, an international law firm, from 2013 to 2018 where he represented clients in a broad range of corporate matters. Prior to Proskauer Rose LLP, Mr. Mano was in private legal practice where he represented clients in the life sciences industry in a broad range of corporate matters. Mr. Mano received a B.A. in Political Science and Sociology from Saint Michael's College and a Juris Doctor from Washington University School of Law.- Michael Mano，于2020年12月加入Karyopharm，担任高级副总裁、总法律顾问和秘书，拥有超过15年的法律经验。在加入Karyopharm之前，Mano先生曾于2018年1月至2020年12月担任上市生物技术公司渤健业务发展方面的法律顾问，在那里他支持渤健的全球业务发展平台。在此之前，他于2013年至2018年担任国际律师事务所Proskauer Rose LLP的高级法律顾问，在那里他代表客户处理广泛的公司事务。在加入Proskauer Rose LLP之前，Mano先生从事私人法律业务，在那里他代表生命科学行业的客户处理广泛的公司事务。Mano先生在圣迈克尔学院获得政治学和社会学学士学位，在华盛顿大学法学院获得法学博士学位。
- Michael Mano,joined Karyopharm as Senior Vice President, General Counsel and Secretary in December 2020 with over 15 years of legal experience. Prior to joining Karyopharm, Mr. Mano served as Counsel, Business Development for Biogen, a public biotechnology company, from January 2018 to December 2020, where he supported Biogen's global business development platform. Prior to that he was Senior Counsel at Proskauer Rose LLP, an international law firm, from 2013 to 2018 where he represented clients in a broad range of corporate matters. Prior to Proskauer Rose LLP, Mr. Mano was in private legal practice where he represented clients in the life sciences industry in a broad range of corporate matters. Mr. Mano received a B.A. in Political Science and Sociology from Saint Michael's College and a Juris Doctor from Washington University School of Law.
- Stuart Poulton
Stuart Poulton，2022年2月加入Karyopharm，担任战略和投资组合管理高级副总裁，自2022年8月起担任Karyopharm Therapeutics Inc.执行副总裁、首席开发官。Poulton先生于2019年至2022年1月在公共生物制药公司艾伯维公司担任临床开发运营副总裁，并于2016年至2019年担任投资组合项目管理副总裁。在此之前，Poulton先生曾在安进担任多个职务，包括2013年至2016年担任全球项目管理执行董事；2012年至2013年担任亚洲Regional管理团队全球项目管理总监；2007年至2012年担任全球项目管理总监，2006年至2007年担任临床研究规划高级经理。Poulton先生的职业生涯始于礼来公司的临床运营部门。Poulton先生在澳大利亚悉尼大学获得药理学和化学学士学位，在澳大利亚新南威尔士大学获得市场营销硕士学位。
Stuart Poulton,joined Karyopharm as Senior Vice President, Strategy and Portfolio Management in February 2022 and has served as Karyopharm Therapeutics Inc. Executive Vice President, Chief Development Officer since August 2022. Mr. Poulton served as Vice President, Clinical Development Operations at AbbVie Inc., a public biopharmaceutical company, from 2019 to January 2022 and as Vice President, Portfolio Program Management from 2016 to 2019. Prior to that, Mr. Poulton served in several roles at Amgen, including as Executive Director, Global Program Management from 2013 to 2016; as Director, Global Program Management, Asia Regional Management Team, from 2012 to 2013; as Director, Global Program Management, from 2007 to 2012 and as Senior Manager, Clinical Study Planning from 2006 to 2007. Mr. Poulton started his career at Eli Lilly and Company in clinical operations. Mr. Poulton received his B.Sc. in Pharmacology and Chemistry from the University of Sydney, Australia and a M.Com. in Marketing from the University of New South Wales, Australia.- Stuart Poulton，2022年2月加入Karyopharm，担任战略和投资组合管理高级副总裁，自2022年8月起担任Karyopharm Therapeutics Inc.执行副总裁、首席开发官。Poulton先生于2019年至2022年1月在公共生物制药公司艾伯维公司担任临床开发运营副总裁，并于2016年至2019年担任投资组合项目管理副总裁。在此之前，Poulton先生曾在安进担任多个职务，包括2013年至2016年担任全球项目管理执行董事；2012年至2013年担任亚洲Regional管理团队全球项目管理总监；2007年至2012年担任全球项目管理总监，2006年至2007年担任临床研究规划高级经理。Poulton先生的职业生涯始于礼来公司的临床运营部门。Poulton先生在澳大利亚悉尼大学获得药理学和化学学士学位，在澳大利亚新南威尔士大学获得市场营销硕士学位。
- Stuart Poulton,joined Karyopharm as Senior Vice President, Strategy and Portfolio Management in February 2022 and has served as Karyopharm Therapeutics Inc. Executive Vice President, Chief Development Officer since August 2022. Mr. Poulton served as Vice President, Clinical Development Operations at AbbVie Inc., a public biopharmaceutical company, from 2019 to January 2022 and as Vice President, Portfolio Program Management from 2016 to 2019. Prior to that, Mr. Poulton served in several roles at Amgen, including as Executive Director, Global Program Management from 2013 to 2016; as Director, Global Program Management, Asia Regional Management Team, from 2012 to 2013; as Director, Global Program Management, from 2007 to 2012 and as Senior Manager, Clinical Study Planning from 2006 to 2007. Mr. Poulton started his career at Eli Lilly and Company in clinical operations. Mr. Poulton received his B.Sc. in Pharmacology and Chemistry from the University of Sydney, Australia and a M.Com. in Marketing from the University of New South Wales, Australia.